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Abstract
Background—Evidence on economically efficient strategies to lower blood pressure (BP) from
low- and middle-income countries remains scarce. The Control of Blood Pressure and Risk
Attenuation (COBRA) trial randomized 1341 hypertensive subjects in 12 randomly selected
communities in Karachi, Pakistan, to three intervention programs: combined home health
education (HHE) plus trained general practitioner (GP); 2) HHE only; 3) trained GP only. The
comparator was no intervention (or usual care). The reduction in BP was most pronounced in the
combined group. The present study examined the cost-effectiveness of these strategies.
Methods and Results—Total costs were assessed at baseline and 2 years to estimate
incremental cost effectiveness ratios (ICER) based on (a) intervention cost; b) cost of physician
consultation, medications and diagnostics, changes in lifestyle, and productivity loss and (c)
change in systolic BP. Precision of the ICER estimates was assessed by 1000 bootstrapping
replications. Bayesian probabilistic sensitivity analysis was also performed.
The annual per participant cost associated with the combined HHE plus trained GP, HHE alone,
and trained GP alone were $3.99, $3.34, and $0.65, respectively.
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HHE plus trained GP was the most cost effective intervention with an ICER of $ 23 (6 to 99) per
mm Hg reduction in systolic BP compared to usual care and remained so in 97.7% of 1000
bootstrapped replications.
Conclusions—The combined intervention of HHE plus trained GP is potentially affordable and
more cost effective for BP control than usual care or either strategy alone in some communities in
Pakistan, and possibly other countries in Indo-China with similar healthcare infrastructure.
Keywords
blood pressure; health care costs; health services research; cost effectiveness
Introduction
Cardiovascular diseases (CVD) have become the leading cause of death worldwide, and will
particularly affect younger adults in developing countries, with major adverse consequences
for national economies. Hypertension confers the highest attributable risk of death from
CVD. 1
The burden of hypertension has reached epidemic proportions in Indo-Asian countries,
affecting a third of adults in Pakistan. 2 However, public spending on health, especially
chronic disease prevention, remains abysmally low in the face of competing priorities. 3
Private providers are the front line care givers and are visited frequently. However, serious
deficiencies have been identified in their knowledge and practices with regards to the
management of hypertension. 4 Furthermore, there are no national strategies for the control
of hypertension or similar efforts to enhance care by private providers. As highlighted in the
recent Institute of Medicine Report on Cardiovascular Diseases in low and middle income
countries, advocating both public and private sector changes requires locally obtained
relevant empirical evidence on sustainable, cost effective and affordable population-based
strategies for the prevention and control of hypertension, which is scarce. 5Recently, we
reported the results of large cluster randomized factorial design trial on community based
strategies of home health education (HHE) and training of general practitioners (GPs) to
control high blood pressure (BP). 6 We found that BP declined in all groups, but the
reduction was most pronounced in those randomized to the combined group of both
strategies than either or no intervention groups.
However, neither the cost nor the cost effectiveness of the interventions was reported. 5 This
information is essential for policymakers and health planners as clinically effective
interventions may not necessarily represent value for money compared to the alternatives
studied in this resource-poor country. 7
We therefore conducted these analyses to determine 1) the cost of the interventions from the
affordability perspective of the policymaker, 2) the incremental cost effectiveness of the
total health care costs related to the interventions compared to usual care in terms of per mm
Hg reduction in BP from the societal perspective. An intervention cost from a policymaker’s
perspective within 10% of the existing national healthcare (government spending) budget
was considered affordable. 8 The lowest incremental cost effectiveness ratio (most BP
reduction at least total health care cost relative to usual care) that was also significantly
different compared to usual care, ie bootstrapped 95% CIs also consistent with the mean
value in direction and magnitude, was considered most cost-effective. We hypothesized that
the combined HHE plus GP intervention would be more cost-effective than single
interventions or usual care.
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Settings and Patients
The Control of Blood Pressure and Risk Attenuation (COBRA) trial was a cluster
randomized controlled trial with a 2×2 factorial design to determine the impact of family
based HHE and/or special training of GPs on the BP levels of adults aged 40 years or above
with hypertension (registration number NCT00327574, ClinicalTrials.gov). 6 The sampling
frame and study design details have been described previously. 6 Briefly, multistage cluster
sampling techniques were used to randomly select 12 communities (with about 250
households each) from middle to low income areas in Karachi. Individuals aged 40 years or
over residing in the 12 clusters with known hypertension or with consistently elevated BP on
two separate visits (mean of last two of three measurements of systolic pressure ≥140 mm
Hg or mean diastolic pressure ≥90 mm Hg) were eligible for inclusion in the study. The 12
clusters were then randomly assigned to four groups of 3 clusters each: HHE, trained GP,
HHE plus trained GP, and no intervention.
Home Health Education
Six community health workers (CHW) (one for each cluster) trained over six weeks
provided advice at 3-monthly intervals on the importance of engaging in moderate physical
activity; maintaining normal body weight; reducing salt intake; maintaining an adequate
intake of potassium; and consuming a diet rich in fruit, vegetables, and low-fat dairy
products and low in saturated and total fat (including sample recipes for culturally
acceptable and economically feasible food products), and smoking cessation. 9 This
intervention was modelled on the existing Lady Health Workers program in Pakistan. The
details of training have been published previously. 6
General Practitioner Training
All GPs in the six study areas assigned to this intervention were invited for training, with the
realistic aim to train at least two-thirds of all GPs from each area. The annual training was a
one day session focused on standard treatment for the management of hypertension, based
on the seventh report of the Joint National Committee (JNC 7) and the Fourth Working
Party of the British Hypertension Society guidelines modified for the Indo-Asian
population. 1011
All study participants aged 40 years or above with hypertension were advised to consult a
local GP. Those in the clusters randomized to the trained GP arm were given a list of trained
GPs within their cluster. However, GP selection remained the choice of the participants.
There was no provision for supplying medications, or reimbursing fee-for-healthcare
services in the study. The participation by subjects and GPs was voluntary.
Screening and Recruitment
All households in each cluster were visited, and informed consent was obtained for
screening from all adults aged 40 and above, who then underwent measurement of BP 3
times with a calibrated automated device (Omron HEM-737 IntelliSense; Omron Healthcare
Inc., Vernon Hills, Illinois, US) in the sitting position after 5 minutes of rest. Those with an
elevated BP and not on antihypertensive medication were visited again for re-measurement
of BP 1–4 weeks after the initial visit. If mean BP remained elevated, these individuals were
invited to participate. In addition, those with known hypertension were also invited to
participate, irrespective of measured BP.
Hypertensive adults were evaluated by trained field staff, masked to randomization status, at
baseline and 4-monthly intervals when three consecutive BP readings, were taken.
Information on diet (food frequency and expenditure on fruits and vegetables), physical
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activity (international physical activity questionnaire), current antihypertensive medications,
frequency of visits to health providers in the last two weeks, and expenditure on healthcare
costs (provider fee, medications and laboratory costs), and any hospitalizations were
collected. Information on days of work lost due to illness during this period was recorded.
BP was measured as described above. The planned median duration of follow-up was 2
years.
Costs
We estimated the cumulative intervention costs over 2 years. These costs included
personnel, equipment, and training material and supplies for development of curricula, and
transport and other operational expenses over 2 years (Table 2). Personnel costs for the
interventions included salaries and fringe benefits of faculty, a nutritionist (for HHE), and
community health workers (seven full time for HHE and six part-time field workers for the
trained GP group). To account for office rent and maintenance, an administrative cost of
30% was applied to intervention costs. Since one of the goals was to assess the affordability
from policymaker’s perspective, and implications on public funds, only the intervention cost
was used for this purpose The cost effectiveness analyses were performed from a societal
perspective, so needed to account for total health care costs. These costs included the cost of
intervention, patient costs on health care and related life style (diet), and productivity losses.
The patient costs for health care included payments made by patients to the health care
provider, the cost of purchasing medications and expenditure on diagnostics. Patient data on
costs were collected from participants at baseline and final visit by questionnaire. The
questionnaire was administered in the homes of respondents by trained interviewers.
Participants (from all four groups) were asked to provide detailed information on any
medical consultations, medications purchased, medical tests conducted and periods of
hospitalization during the previous 2 weeks. These cost data were annualised to determine
the direct annual healthcare cost for all four groups at baseline and final follow-up visit.
(Table 3a) This rationale was consistent with our analysis of the primary effectiveness
outcome of change in BP, as reported previously. 6 For the cost effectiveness analysis, the
difference in annualised cost from baseline to follow-up for each group was projected over
two years, with adjustment for inflation.
The cost of fruit and vegetables was also included in the societal aspect of life style
modification. Information on fruit and vegetables, and meat purchased by the household
during the previous 2 weeks was collected, and since interventions were delivered at the
community level, the denominator for per-patient calculation was all subjects aged 5 years
and above.
Following the recommendation of Gold et al on the importance of accounting for patient and
caregiver’s time, values for productivity losses were imputed for the opportunity costs to
participants and caregivers; irrespective of whether or not they were in paid employment. 12
We used the average market wage rate for men and women in urban Sindh (Government of
Pakistan, 2009) as the value of time lost. 1213 Productivity losses resulting from illness and
treatment were imputed for participants and projected over 2 years.
Since BP screening by community health workers was common to all four randomized
groups, the cost of screening was not considered in the comparative analysis. However, it
was included in estimating the impact of up-scaling strategies on the national health budget,
and for this it was assumed that the BP monitors would have a useful life of 5 years with no
resale value after that.
All costs are reported in US $ at the 2007 rate. To control for inflation, all costs were
inflated to prices in 2007, using the gross domestic product deflator of 7.7% for Pakistan. 14
Jafar et al. Page 4
Circulation. Author manuscript; available in PMC 2012 April 11.
U
KPM
C
 Funders G
roup Author M
anuscript
U
KPM
C
 Funders G
roup Author M
anuscript
The mean exchange rate for the year was used to convert costs from Pakistan rupees into US
dollars. To adjust for time preference all costs and effects were discounted; following the
International Society for Pharmacoeconomics and Outcomes Research ISPOR guidelines an
annual discount rate of 5% over 2 years was used. 1516
Effectiveness
The primary outcome measure for the study was the change in systolic BP from baseline to
the last follow-up visit. The secondary outcome measure was the proportion of participants
with controlled BP (<140 mm Hg for systolic BP and <90 mm Hg for diastolic BP) at the
last follow-up visit.
Statistical Analysis
We compared the costs of each randomized intervention to the no intervention group on an
intention- to- treat principle.
Incremental cost-effectiveness ratios were computed to compare the additional costs and
effects of each intervention over the other 12 Uncertainty in the point estimate of the ICERs
was investigated using a non-parametric bootstrap with 1000 replications varying the BP
effects, while costs remained the same. 8 The bootstrap was used to estimate 95%
confidence intervals (CI) around differences in ICERs between randomized groups and to
produce scatter plots for the interventions on a cost-effectiveness plane. (Figure 1) 1718
Cost Per CVD DALY averted—To facilitate comparison with other programs for
competing priorities, the most cost-effective of the alternatives considered was expressed in
terms of the cost per disability adjusted life year (DALY) averted. The DALY is a generic
measure of the burden of disease that combines healthy life years lost because of premature
mortality with those lost as a result of disability. 19 The metric thus enables assessment of
burden of disease, and is helpful for policymakers for resource allocation during health
planning.
To assess the impact on the national health budget, the per participant cost of intervention
was translated into per-capita cost for the population of Pakistan from the policymakers
perspective. In addition, the per- capita cost per CVD DALY averted analysis was
performed from both the policymakers’ and the societal perspectives.. Since the relationship
between the fall in BP and the impact on CVD events is linear and well defined, a reduction
in 5 mm Hg in BP was assumed to lead to 20% reduction in CVD DALYs. 20, 2122The cost
of one CVD DALY averted was computed for annual burden of 3,176,000 DALYs from
CVD for Pakistan, as observed in GBD Study 2004. 23
Sensitivity Analysis
We undertook a number of sensitivity analyses to assess the impact of uncertainty on the
estimates of cost-effectiveness. These included different discount rates of costs and values of
SBP effectiveness, exclusion of productivity losses, and additional cost inputs including
lifestyle factors such as smoking, expense related to meat consumption, and productivity
loss of caregiver’s time while chaperoning GP visits, and exclusion of lifestyle related costs
(ie fruit and vegetables). Probabilistic sensitivity analysis using Bayesian principles was
conducted to assess simultaneous changes in all patient level variables involved in the costs
and main effects. Monte Carlo simulation was performed to determine the mean costs,
effects on BP, and ICERs among the treatment groups. We also computed ICERs for the
primary outcome incrementally to compare the least costly with the next more costly
intervention. 24
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From the societal perspective the incremental cost per CVD DALY averted was also
computed based on incremental cost estimates from the simulated models. In addition, CVD
DALYs averted were computed for declining persistence of effect despite continued
intervention assuming a reduction of 1% annually thus ranging from 20% to 10%; or a 50%
reduction in benefit.
Finally, we also performed additional sensitivity analysis to estimate the cost effectiveness
of the interventions in a high income country like the United States assuming similar
effectiveness on blood pressure while applying US cost estimates. The latter was done by 1)
converting all costs in Pakistan rupees to US international dollar equivalent corresponding to
purchasing power parity for the year 2007 (1 US $=22.7 Pakistan Ruppee); and 2) specific
replacement of itemized costs in Pakistan with US estimates related to GP consultation fee,
personnel and health workers’ salaries, medications, and diagnostics which take into account
the higher healthcare prices in the US. 25 The cost of one CVD DALY averted was based on
the ICER for US cost data, and computed for an annual burden of 5,853,000 DALYs from
CVD, as observed in the GBD Study 2004.
Results
Overall 1341 study participants were randomised: 332 to HHE plus trained GP, 348 to HHE
only, 335 to trained GP only, and 326 to no intervention. The baseline characteristics of
hypertensive adults in the randomized groups are shown in Table 1. A total of 1044 subjects
(78%) completed 2 years of follow-up.
Intervention and resource utilisation costs
The annual per participant intervention costs (i.e. from the perspective of the policymaker)
varied substantially for the intervention groups: the most expensive being the joint
intervention group, around 4 times higher than the GP intervention only group (Table 2).
The per participant expenditure on direct healthcare including physician consultation,
medications and diagnostics at baseline and follow-up are shown in Table 3a. The use and
associated cost of antihypertensive medications increased from baseline to follow-up in all
groups; this increase was more pronounced in the groups with trained GPs (Table 3b). The
decrease in expenditure on fruits and vegetables was most marked in the combined HHE
plus trained GP group, probably reflecting a shift to low cost seasonal produce as advised.
However, despite emphasis during GP training, that thiazide diuretics be the first-line agent
for most hypertensive patients, their use remained low (less than 3% in all groups).
Effectiveness
As reported previously, systolic BP declined in all four groups. The decline in systolic BP
(adjusted for age, sex, and baseline BP) was significantly more pronounced in the HHE plus
trained GP care group (11 mm Hg, p=0.001) as compared to the other groups (about 6 mm
Hg in each). We also detected a significant interaction in the proportion of patients with
controlled BP (P < 0.001) between the main effects of GP training and HHE. Thus, a
substantially greater proportion of patients (56.9%) achieved controlled BP in the HHE and
trained GP group than in the other groups (trained GP-only, 29.0%; HHE-only, 23.0%; no
intervention, 27.3%; P for difference among groups <0.003). The mean per-capita
expenditure by respondents on all healthcare over 2 years is shown in Table 4. While the
direct costs for HHE plus trained GP were highest at $189, the reported productivity loss
was greatest for the trained GP group. The expenditure on fruit and vegetables was also
highest in the latter, in part responsible for the overall highest costs at $538 for the trained
GP group.
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Incremental Cost effectiveness ratios
From a societal perspective, the combined intervention of HHE plus trained GP yielded a
bootstrapped ICER of $ 23 (95% CI 6 to 99) per mm Hg reduction in systolic BP compared
to no intervention (usual care) (Table 4). When discounted at 5% the combined intervention
of HHE plus trained GP yielded an ICER of $ 23 (7 to 101) per mm Hg reduction in systolic
BP compared to no intervention (usual care). Whether discounted or undiscounted the
ICERs associated with the single interventions were less cost-effective (Table 4) as their
confidence intervals were wide in magnitude and direction ranging from dominant to
positive ICERs. Scatter plots of the bootstrapped ICERs illustrate these results (Figure 1).
Per-capita cost of intervention and cost per CVD DALY averted for Pakistan
Based on hypertension prevalence of about 18% in Pakistani adults aged 15 years and
older 2 (and 60% of the population is in this age range) the estimated cost of annual
combined intervention cost of HHE and GP training of $3.99 per participant translates into
an annual per capita cost of $0.43 for the 170,000,000 population of Pakistan. 26 From a
policymaker’s perspective, the HHE plus GP training intervention was estimated to cost
$115 per CVD DALY averted. From a societal perspective, the incremental cost of the
combined intervention versus usual care was $1226 per CVD DALY averted. Moreover, the
additional cost of screening for BP would be about $0.06, thus cumulative per capita cost
incurred to scale-up the combined HHE plus GP intervention and BP screening would be US
$ 0.49.
Sensitivity analyses
Sensitivity analysis of the outcome parameter by varying change in systolic BP from the
trial during computation of 95% limits of ICER confirmed the cost-effectiveness of HHE
plus trained GP over the other interventions. Further, exploration of the implications of
simultaneous alteration in costs and effects, application of discount rates of 3% and 10% (as
recommended by ISPOR)1, additional and reduced costs, as well as application of US cost
estimates, all revealed cost-effectiveness of combined HHE plus trained GP over trained GP,
HHE or no intervention. (Table 5a). The cost per DALY averted for Pakistan increased from
$115 to $230 at the policymaker level, and from $1226 to $2451 at the societal level with
modelling declining persistence of cardiovascular benefit from 20% to 10%, respectively.
(Table 5b)
The approach of comparing the least to the next more costly intervention (ie HHE compared
with the combined intervention of HHE plus trained GP) yielded an ICER of $77.8 (19.9 to
275.8) per mm Hg reduction in BP, which translates into $ 3600 per CVD DALY saved.
From a societal perspective for the US, based on the prevalence of hypertension of 24% as
observed in the third National Health and Nutrition Examination Survey (NHANES III) in
adults aged 18 years and older 27 (and about 80% population in this age range), the
estimated cost per DALY was I$5,770 for the international purchasing power parity cost
replacement, and $40,466 per DALY averted for itemized replacement of costs.
Discussion
We found that the combined intervention of HHE by lay health workers and management by
trained GPs was more cost effective for lowering BP compared to trained GP, HHE or no
intervention in the communities in Karachi. The combined HHE plus GP group was the
most cost-effective compared to other interventions, was associated with the bootstrapped
ICER of $ 23 (6 to 99) per mm Hg reduction in systolic BP compared to usual care, and
remained so in 97.7% of 1000 bootstrapped replications. According to the US Panel on
Cost-effectiveness in Health and Medicine there are no absolute standards for accepting an
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intervention as “cost-effective” or “not cost-effective” on the basis of cost effectiveness
ratios. 28 However, the incremental cost effectiveness ratio (ICER), offers a comparative
estimate relative to the next best alternative, and is therefore more informative for decision
making.
Our analyses indicate that from the policymakers’ perspective the combined HHE and
trained GP intervention was the most costly (annual per participant $3.99) of the three
interventions. (Table 2) However, the combined programme was also the most effective. On
the other hand the HHE only intervention was costly (annual per participant $3.34) and less
effective compared to no intervention; whereas, the trained GP only intervention had lower
costs (annual per participant $0.65) but lower effects. On the other hand from a societal
perspective, the incremental costs relative to usual care were lowest in HHE, albeit there
was no difference in BP levels compared to usual care (Figure 1). The trained GP group had
high costs and no difference in benefit. However, the combined HHE and trained GP
intervention had higher costs but also produced a greater benefit than usual care; thus
remained the most cost-effective intervention.
Current prevention strategies promoted by WHO focus on combination drug treatment (low
dose antihypertensives, statin and aspirin) to manage patients’ overall cardiovascular risk
profile which is considered cost-effective for most low and middle income countries. 14
While such an approach is attractive, the use of multiple drugs is more expensive and
combined formulations are not yet available. Moreover, the use of risk charts and the
clinical assessment required is more complicated than making a BP measurement. A
systematic review of use of risk charts did not show any strong evidence of improvements in
care or risk factor outcomes 29
We utilized the existing healthcare infrastructure in Pakistan to deliver the intervention,
hence ensuring logistical feasibility. The community general practitioners trained during the
study were mostly private contractors who continued to provide care on their usual fee-for
service model. Consistent with the pattern of out-of-pocket coverage for medications in
Indo-Asia, antihypertensive drugs were also primarily bought by the patients. The door to
door service of HHE replicated the existing publically funded Lady Health Workers
Programme of Pakistan (LHWP) in terms of credentials, frequency of visits, and duty hours
of the home educators. The LHWP has been implemented for about two decades, and
provides immunization, basic maternal and preventive child care services. 30 The synergistic
benefit of HHE and GP training on BP lowering in our study was probably due to mutual
reinforcement of health care messages. 6 Thus, we show that modest investment in
strengthening the existing private and public health sector for BP control can lead to
substantial improvement in patient outcomes from a societal perspective. Moreover, the
demonstration of success in a largely private physician dominated healthcare infrastructure
suggests that the observed benefit is likely to enhance further in the long term by reduction
in market failure in the prevention of chronic disease. 31
Our results indicate that the majority (>60%) of direct healthcare costs in hypertensive
subjects were spent on medications. The proportional cost of medications became even more
substantial after two years in the two groups receiving care from trained GPs. (Table 3b)
The subjects in these groups were also more likely to be receiving antihypertensive agents
perhaps reflecting the effectiveness of the update in management guidelines that
underscored the value of appropriate use of antihypertensive agents. (Table 3b) These
findings are supported by a nested study in our population linking GP training with better
adherence to antihypertensive medications which was also linked with improved BP
control. 32 Additional efforts to overcome barriers to thiazide diuretics are likely to further
enhance economic efficiency of the intervention, as indicated by our results where overall
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costs reduced by more than 50% with an assumption that these agents were used as first-line
anti-hypertensive agents by patients assigned to trained GPs (Table 5b)
The combination of low cost and effectiveness in achieving target BP with the HHE plus
trained GP programme compares favourably with the results for a similar programme
deemed cost-effective in Georgia, USA, where BP control rates of 68% were achieved with
per-capita expenditure of $7.8. 33 While outcomes data are not reported, a train the trainers
intervention for BP control costing the same has also been successfully implemented across
Kyrgyzstan, a lower middle income country. The estimated annual per capita combined
intervention cost of $0.43 (or $0.49 inclusive of BP screening) is about 10% of the current
national budgetary allocation to health ($700 million) in Pakistan, and only 14% of the
current $2.97 per capita spending on maternal and child health programs. 26 Moreover, even
this cost will be somewhat offset when the program is implemented on the existing LHWP,
as considerable resource sharing is expected. The per capita GDP of Pakistan is about $881
(World Bank estimate for 2007)); and the cost per CVD DALY saved from a societal
perspective of the combined HHE plus trained GP was $1226 per DALY saved.
According to the World Health Organization, an intervention that saves one DALY for less
than three times the gross domestic product (GDP) per capita is considered cost-effective,
while one that saves a DALY for less than one GDP is considered very cost-
effective. 34These recommendations are consistent with the <$ 1000 per CVD DALYS
saved being highly cost effective for low income countries by The Disease Control Priorities
Project (DCPP). 35 Moreover, all the sensitivity analyses indicate that the estimates
associated with the combined intervention fall within the range qualifying it to be cost-
effective. Furthermore, the $115 per DALY saved with the combined intervention from the
policymaker’s perspective is comparable to the existing maternal and neonatal care
programs in South Asia costing $127-394 per DALY averted .8 We believe our findings
have significant public health implications for a substantial proportion of the world’s
population in Indo-China, Africa, as well as other countries where the prevalence of
hypertension is high, the mixed public-private healthcare system is comparable for up-
scaling strategies using non-physician workforce and training existing healthcare providers
to achieve a similar effect, and a significant share of the health care costs are borne out-of
pocket. 23, 3637Thus, the combined intervention of GP training plus HHE intervention could
potentially be an effective and affordable intervention for many low income communities
worldwide. 2838
Our analysis has potential limitations. Most studies of cost effectiveness use the metric of
disability or quality adjusted life years based on deaths and disabilities from myocardial
infarctions and strokes. However, the follow-up duration in COBRA was short as it was not
powered to assess differences in these hard outcomes. Instead, the primary measure of
effectiveness was determined by reduction in BP, an acceptable outcome measure for cost
effectiveness studies 3940, which is well documented to translate into reduction in
cardiovascular morbidity and mortality. 22, 41 Second, we did not take into account any cost
incurred during hospitalizations of subjects in the four groups. However, the number of
hospitalizations was too few to make a significant difference to the results (less than 1% of
subjects). Nevertheless, a larger study for a longer duration is likely to show an even greater
benefit of the combined HHE plus trained GP intervention on potential relief from the
financial burden of catastrophic illness due to acute cardiovascular events, which often
perpetuates the cycle of poverty in low income countries. 42 Third, our study was conducted
in a developing country setting, hence generalizabilty to high income settings with greater
opportunities for physician education and public awareness remains unknown. 43Further, the
cost differentials, especially those related to healthcare, would be limited. However,
sensitivity analysis assuming similar benefit and replacing costs incurred in Pakistan with
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those estimated for the US setting for comparable services using international purchasing
power parity (I$5,770 per CVD DALY averted) as well as after itemized replacements with
rather excessive healthcare costs in the US (40,644 per CVD DALY averted), both were
within one per capita GDP of the US (World Bank estimate ($46,627 for 2007, hence
revealed consistent findings. Thus, the combined intervention of HHE by lay health workers
plus trained GP is likely to be cost effective in industrialized countries with high human
resource costs as well. Finally, about 22% of subjects were lost to follow-up. However, they
were balanced among the randomized groups. 6 Moreover, we analyzed both costs and
effects on intention-to-treat principle. The strengths of our study are the use of empirical
cost and effectiveness data and the consistency of results over a range of sensitivity analyses
including those not accounting for productivity losses, as well as including additional cost
inputs which further enhanced the benefit of the combined HHE plus trained GP
intervention by lowering ICER to 17 (5 to 75) (Table 5a), and after assuming a substantial
reduction in effect, albeit evidence from meta-analysis of clinical trials suggests persistence
of effect. 44Further, our study was built on the existing health system which supports the
feasibility, acceptability and high likelihood of wide implementation and sustainability if the
intervention is scaled up. Thus we believe our findings are robust and of high validity.
In conclusion, the present analyses show that the combined intervention of HHE plus trained
GP in management of hypertension is potentially affordable and significantly more cost
effective than usual care or either strategy alone in the communities of Karachi, Pakistan.
These results provide valuable guidance to policymakers for up-scaling the combined cost-
effective intervention now as well as conducting further in-depth research on improving
CVD outcomes in Pakistan and other resource-challenged countries with a rising burden of
high blood pressure demanding immediate public health attention. 45
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High blood pressure contributes the greatest attributable risk to mortality worldwide.
However, evidence on economically efficient strategies to lower blood pressure (BP)
from low- and middle-income countries (LIMCs) remains scarce.The Control of Blood
Pressure and Risk Attenuation (COBRA) trial randomized 1341 hypertensive subjects in
12 randomly selected communities in Karachi, Pakistan, to three intervention programs
compared to usual care: 1) combined home health education (HHE) by lay health
workers plus management by trained general practitioner (GP); 2) HHE only; 3) trained
GP only.The HHE intervention was modeled on the existing Lady Health Workers
Programme in Pakistan and provided education on healthy diet, physical activity, and
tobacco cessationin the home setting at 3 monthly intervals. GP training was an annual
one-day session on optimal hypertension management.
Total costs and effect were assessed at baseline and 2 years to estimate incremental cost
effectiveness ratios (ICER) based on (a) intervention cost; b) cost of physician
consultation, medications and diagnostics, changes in lifestyle, and productivity loss
and(c) change in systolic BP. We found that combined HHE plus GP intervention led to
most BP reduction for the cost (incremental cost effectiveness ratio of $ 23 per mm Hg
reduction in systolic BP compared to usual care), and remained so in 97.7% of 1000
bootstrapped replications.The estimated cost of the combined intervention was $115 per
disability adjusted life year(DALY) averted from the policymaker’s and $1226 per
DALY averted from the societal perspective, and $0.43 per capita population per year
would be needed to scale up the intervention in Pakistan. Thus, the combined
intervention of GP training plus HHE intervention could potentially be an effective and
affordable strategy for many LMICs worldwide urgently in need of efforts to prevent and
control hypertension.
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Figure 1.
Incremental Cost-effectiveness plane at 5% discounting. Bootstrap replications showing the
effect differences in change in blood pressure between randomized treatment programs
versus usual care on the x-axis. An effect of larger than zero means greater reduction in BP
in the treatment group. The proportions on the graphs indicate the percent of values out of
the1000 replications for which effect difference was greater than 0. The y-axis shows the
cost difference between intervention versus usual care. Positive values suggest the
intervention is more expensive compared to usual care and vice versa.
Relative to the control group (usual care) at the origin, the incremental costs are divided
across the horizontal axis of the plane (higher positive, lower negative) and the incremental
effect by the vertical axis (higher to the right, lower to the left). Thus, each quadrant has a
different implication for the choice of intervention.
Interventions with ICERs falling in the southeast quadrant would be more effective and less
costly, and therefore always cost-effective relative to the comparator. Interventions with
ICERs in the northwest quadrant would be less effective and more costly, and not cost-
effective.
An intervention with ICERs falling in the northeast quadrant would be more effective but
also more costly; consequently, a trade-off between costs and effects would need to be
considered, as this would represent a situation where interventions may be cost-effective
compared to usual care, depending upon the value at which the ICER is considered good
value for investment
HHE=home health education; GP=trained general practitioner group.
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Table 1
Comparison Baseline Participant Characteristics by Interventions
Characteristic HHE and
Trained GP
HHE Only Trained GP
Only
No
Intervention
Cluster characteristics
 Clusters, n 3 3 3 3
 Households, n 656 673 657 664
 Mean residents per household
 (SD), n
6.5 (3.0) 6.7 (3.0) 6.6 (3.0) 6.4 (3.1)
 Number of GP’s 61 61 58 69
Patient characteristics
Households, n 278 283 281 275
Hypertension, n 332 348 335 326
Mean age (SD), y 54.0 (11.5) 52.7 (11.4) 55.3 (11.5) 53.3 (11.5)
Men, n (%) 112 (33.7) 133 (38.2) 138 (41.2) 118 (36.2)
Education level, n (%)
 Illiterate 131 (39.5) 110 (32.8) 151 (43.4) 162 (49.7)
 Primary or higher 201 (60.5) 197 (56.6) 225 (67.1) 164 (50.3)
Current Smoker, n (%) 23 (37.7) 36 (48.6) 46 (54.8) 37 (56.9)
Physical activity MET score ≥840,
n (%)*
96 (28.9) 116 (33.3) 96 (28.7) 148 (45.4)
Low socioeconomic status, n (%)† 232 (69.9) 246 (70.7) 188 (56.1) 266 (81.6)
Sought ambulatory care in last two
weeks, n (%)
109 (32.8) 113 (32.5) 94 (28.1) 105 (32.2)
Total # of GP visits in last two
weeks
278 279 201 287
Employment Status, n (%)
 Currently Employed 99 (29.8) 107 (30.7) 109 (32.5) 92 (28.2)
 Jobless 9 (2.7) 13 (3.9) 13 (3.9) 12 (3.7)
 Housewives 190 (57.2) 199 (57.2) 178 (53.1) 191 (58.6)
 Retired 34 (10.2) 29 (8.3) 35 (10.4) 31 (9.5)
GP = general practitioner; HHE = home health education; MET = metabolic equivalent.
*
Calculated as total MET minutes/wk = walk (MET minutes × days) + moderate (MET minutes × days) + vigorous (MET minutes × days).
†
Monthly household income < $70 as reported by the Federal Bureau of Statistics.
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Table 2
Per participant Annual Intervention Cost
Characteristics HHE and Trained GP HHE Only Trained GP
Only
No Intervention
Personnel* 2.77 2.46 0.31 -
Equipment† 0.14 0.14 - -
Training
supplies‡
0.22 0.14 0.08 -
Transport 0.38 0.37 0.01 -
Indirect Cost§ 0.47 0.23 0.24 -
Total 3.99 3.34 0.65 -
All expenses are expressed in US $, valued of exchanges rate based on July 2007 (1 USD=Pak Rs 61)
*
Three Assistant Professors at $1336 per person for 1 month, one nutrition consultant at 5% effort for $70 per month for 24 months; one nutrition
trainer at 50% effort for $185 per month for 24 months; Seven community health workers at $ 123 per person per month over 2 years. In addition,
eight workers for part-time work at $48.4 per person for one month. Two part-time chaperons at $34.6 per month.
†
Three computers for total $2594, one DVD player for $ 112; CDs for $10; for all three interventions
‡
Training manuals and charts printing for $ 750 in groups receiving HHE and $1190 in those with trained GP, Office stationary and photocopies
for $1743 in HHE and $333 in trained GP
§
Office Rent at $4358 (trained GP and HHE groups), Indirect Cost is 30% of all direct costs
Circulation. Author manuscript; available in PMC 2012 April 11.
U
KPM
C
 Funders G
roup Author M
anuscript
U
KPM
C
 Funders G
roup Author M
anuscript
Jafar et al. Page 18
Ta
bl
e 
3a
Pa
tie
nt
 L
ev
el
 C
os
t f
or
 tw
o 
ye
ar
s i
n 
U
S 
$
C
ha
ra
ct
er
is
tic
H
H
E
 a
nd
T
ra
in
ed
 G
P
(n
 =
 3
32
)
H
H
E
 O
nl
y
(n
 =
 3
48
)
T
ra
in
ed
 G
P
O
nl
y
(n
 =
 3
35
)
N
o
In
te
rv
en
tio
n
(n
 =
 3
26
)
* p
-v
al
ue
O
n 
G
P 
C
on
su
lta
tio
ns
 
A
t b
as
el
in
e
61
.9
44
.3
33
.3
45
.6
0.
18
2
 
A
t f
in
al
 v
is
it
16
.3
12
.0
19
.4
17
.7
0.
20
2
O
n 
M
ed
ic
at
io
n
 
A
t b
as
el
in
e
58
.6
46
.4
70
.2
67
.1
0.
23
4
 
A
t f
in
al
 v
is
it
16
2.
2
10
7.
4
13
3.
7
11
7.
5
0.
02
1
O
n 
La
bo
ra
to
ry
 
A
t b
as
el
in
e
13
.2
15
.3
15
.4
6.
1
0.
86
2
 
A
t f
in
al
 v
is
it
40
.7
9.
0
37
.1
45
.6
0.
07
1
To
ta
l E
xp
en
se
s o
n 
H
ea
lth
 C
ar
e
 
A
t b
as
el
in
e
13
3.
7
10
6.
0
11
8.
8
11
8.
8
0.
30
3
 
A
t f
in
al
 v
is
it
21
9.
2
12
8.
3
19
0.
2
18
0.
9
0.
02
1
O
n 
Fr
ui
ts
 &
 V
eg
et
ab
le
s
 
A
t b
as
el
in
e
10
5.
6
10
1.
0
11
4.
3
94
.9
0.
16
1
 
A
t f
in
al
 v
is
it
81
.8
82
.2
98
.0
86
.7
0.
13
2
To
ta
l P
at
ie
nt
 C
os
ts
 o
n 
H
ea
lth
in
cl
ud
ed
 m
ai
n 
an
al
ys
is
†
 
A
t b
as
el
in
e
24
1.
2
19
6.
3
22
9.
1
20
6.
2
0.
29
5
 
A
t f
in
al
 v
is
it
30
6.
0
20
6.
0
28
3.
4
25
8.
8
0.
02
0
M
ea
t C
on
su
m
pt
io
n 
co
st
 
A
t b
as
el
in
e
9.
1
8.
8
10
.1
8.
5
0.
63
2
 
A
t f
in
al
 v
is
it
6.
7
7.
8
10
.0
8.
2
<0
.0
01
Sm
ok
in
g 
C
os
t
 
A
t b
as
el
in
e
0.
5
1.
0
1.
0
1.
0
0.
20
1
 
A
t f
in
al
 v
is
it
0.
6
0.
9
0.
8
0.
8
0.
54
3
A
ll 
ex
pe
ns
es
 a
re
 e
xp
re
ss
ed
 in
 U
S 
$,
 v
al
ue
d 
of
 e
xc
ha
ng
es
 ra
te
 b
as
ed
 o
n 
Ju
ly
 2
00
7 
(1
 U
SD
=P
ak
 R
s 6
1)
* p
-v
al
ue
s a
re
 c
al
cu
la
te
d 
ba
se
d 
on
 ra
w
 d
at
a
Circulation. Author manuscript; available in PMC 2012 April 11.
U
KPM
C
 Funders G
roup Author M
anuscript
U
KPM
C
 Funders G
roup Author M
anuscript
Jafar et al. Page 19
† T
ot
al
 p
at
ie
nt
 c
os
t s
 o
n 
he
al
th
 in
cl
ud
ed
 m
ai
n 
an
al
ys
is
 c
om
pr
is
ed
 o
f G
P 
co
ns
ul
ta
tio
n,
 m
ed
ic
at
io
n,
 la
bo
ra
to
ry
, f
ru
it 
an
d 
ve
ge
ta
bl
e 
ex
pe
ns
es
.
Circulation. Author manuscript; available in PMC 2012 April 11.
U
KPM
C
 Funders G
roup Author M
anuscript
U
KPM
C
 Funders G
roup Author M
anuscript
Jafar et al. Page 20
Table 3b
Use of Antihypertensive Medications by Intervention*
HHE and
Trained GP
(n=332)
HHE only
(n=348)
Trained GP only
(n=335)
No Intervention
(n=326)
At Baseline, % (95% CI) 35.2 (30.3 to 40.5) 39.7 (34.7 to 44.9) 35.5 (30.6 to 40.8) 40.5 (35.3 to 45.9)
At Follow-up, % (95% CI) 49.7 (44.4 to 55) 46 (40.8 to 51.2) 46.3 (41 to 51.6) 48.8 (43.4 to 54.2)
% Change (95% C.I) 14.5 (11.1 to 18.6) 6.3 (4.2 to 9.4) 10.8 (7.9 to 14.5) 8.3 (5.8 to 11.8)
*
The analysis was performed at the patient level so use of more than one antihypertensive medication by a patient was counted as one.
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Table 5a
Sensitivity Analyses
Characteristic HHE and
Trained GP
(n = 332)
HHE Only
(n = 348)
Trained GP
Only
(n = 335)
No
Intervention
(n = 326)
Bayesian Probabilistic
Sensitivity Analysis
 Mean SBP Effect (95% CI)
 mm Hg
10.8 (8.9 to 12.8) 5.6 (3.7 to 7.4) 5.6 (3.7 to 7.5) 5.8 (3.9 to 7.7)
 Total Cost* 499.9 393.2 537.8 457.4
 ICER† 22 (7 to 104) Dominated (dominated to 416) 85 (dominated to 642) -
Excluding productivity losses
 Mean SBP Effect (95% CI)
 mm Hg
10.8 (8.9 to 12.8) 5.6 (3.7 to 7.4) 5.6 (3.7 to 7.5) 5.8 (3.9 to 7.7)
 Total Cost‡ 304.5 226.5 279.4 252.1
 ICER† 28 (8 to 123) Dominated (dominated to 248) 68 (dominated to 267) -
3% Discounting
 Mean SBP Effect mm Hg 10.2 5.3 5.3 5.5
 Total Cost* 477.4 375.5 513.6 436.8
 ICER† 23 (7 to 100) Dominated (dominated to 726) 204 (dominated to 802) -
10% Discounting
 Mean SBP Effect mm Hg 9.0 4.6 4.6 4.8
 Total Cost* 434.9 342.1 467.9 398.0
 ICER† 24 (7 to 104) Dominated (dominated to 749) 211 (dominated to 828) -
Assuming increased use of
thiazides by patients
receiving care by trained GP
groups§
 Mean SBP Effect mm Hg 10.8 5.6 5.6 5.8
 Total Cost§ 459.3 393.2 499.8 457.4
 ICER† 10 (3 to 46) Dominated (dominated to 714) 155 (dominated to 611) -
Additional patient cost
inputs
 On Meat consumption 8.8 9.2 11.0 9.1
 On smoking 0.6 1.0 1.0 1.0
 Mean SBP Effect mm Hg 10.8 5.6 5.6 5.8
 Total Cost∥ 313.9 236.7 291.4 262.2
 ICER† 27 (7 to 116) Dominated (dominated to 227) 92 (dominated to 361) -
Additional patient cost and
productivity losses
Productivity loss for care
giver @ USD 5.72/-
52.9 44.5 69.3 60.2
 Mean SBP Effect mm Hg 10.8 5.6 5.6 5.8
 Total Cost# 562.1 447.9 619.1 527.8
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Characteristic HHE and
Trained GP
(n = 332)
HHE Only
(n = 348)
Trained GP
Only
(n = 335)
No
Intervention
(n = 326)
 ICER† 17 (5 to 75) Dominated (dominated to 883) 248 (dominated to 973) -
Excluding cost of fruit and
vegetables
 Mean SBP Effect mm Hg 10.8 5.6 5.6 5.8
 Total Cost** 392.5 300.7 425.5 366.5
 ICER† 13 (4 to 55) Dominated (dominated to 755) 143 (dominated to 558) -
US costs based on purchasing
power parity
 Mean SBP Effect mm Hg 10.8 5.6 5.6 5.8
 Total Cost†† 1346.2 1058.9 1448.4 1231.9
 ICER† 62 (17 to 266) Dominated (dominated to 1923) 542 (dominated to 2127) -
US costs based on
individually modified
estimates
 Mean SBP Effect mm Hg 10.8 5.6 5.6 5.8
 Total Cost‡‡ 11744.3 9140.0 12139.2 10943.2
 ICER† 416 (113 to 1860) Dominated (dominated to 19722) 3011 (dominated to 11809) -
All expenses are expressed in US $, valued of exchanges rate based on July 2007 (1 USD=Pak Rs 61)
*
Total cost includes total patient costs on health, productivity loss and intervention cost as in the main model
†
Incremental Cost-Effectiveness Ratio calculated based upon boot strapping
‡
The costs include total patient costs on health and intervention costs as in the main model.
§
Cost of medications reduced by a conservative estimate of 50% in 70% of patients on antihypertensive medications in HHE plus GP and trained
GP only groups assuming they were on generic thiazide costing less than 50% of their current medication.
∥
Additional patient cost inputs include cost of smoking cigarettes and expense of meat at baseline and two years of follow-up. All current smokers
were assumed to smoke 1 pack per day priced at average market rate of most commonly sold brand in 2004 for baseline and in 2007 for follow-up.
The actual expenditure on meat was recorded during the study.
#
Additional patient cost and productivity losses. In addition to the patient cost of cigarettes and meat, the productivity loss of the caregiver’s time
was also accounted for.
**
Total cost includes consultation, medication, diagnostics, productivity loss and intervention cost.
††
1 international US = 22.65 Pakistan rupees in terms of purchasing power parity. All costs in rupees were multiplied by 22.7.
‡‡
Total cost computed with the following multiplication factors 85 for GP consultation visits (assuming $70 per visit in the US
(http://www.nber.org/papers/w14568.pdf) and applied to average of $0.73 per visit in the communities in Pakistan; 10 for academic faculty, 15 for
medication costs assuming replacement with generics; 10 for diagnostic tests; 171 for productivity loss (based on average wage $885/week for
2007 in the US as per US Department of Labor Bureau of labor statistics Quarterly Census of Employment and Wages, Annual Averages 2007); 10
for community health workers’ salaries (assuming minimum hourly wage $ 7.75) and 2 for transportation (gas price $2 per/L in the US).
Circulation. Author manuscript; available in PMC 2012 April 11.
U
KPM
C
 Funders G
roup Author M
anuscript
U
KPM
C
 Funders G
roup Author M
anuscript
Jafar et al. Page 24
Table 5b
Sensitivity Analysis: Effect of decline in persistence of effect on CVD DALYs
Benefit in CVD DALYs
saved annually
Cost per CVD DALYs
averted annually based on
Intervention Cost for policy
maker
*Cost per CVD DALYs
annually saved based
on incremental cost at
societal level
*Cost per CVD DALYs averted
annually based on incremental
cost derived from probabilistic
sensitivity analysis at societal
level
20% 115 1226 1208
16% 144 1532 1510
12% 192 2043 2014
10% 230 2451 2416
*
based on incremental total health care costs between combined HHE plus GP intervention versus usual care
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